Skip to main content
Erschienen in: Infection 5/2022

13.05.2022 | COVID-19 | Original Paper

Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients

verfasst von: Verónica Rico-Caballero, Mariana Fernández, Juan C. Hurtado, M. Angeles Marcos, Celia Cardozo, Laia Albiach, Daiana Agüero, Juan Ambrosioni, Marta Bodro, Mariana Chumbita, Lorena De la Mora, Nicole Garcia-Pouton, Ana Gonzalez-Cordón, Gerard Dueñas, Marta Hernandez-Meneses, Alexy Inciarte, Montse Laguno, Lorna Leal, Irene Macaya, Miguel J. Martínez, Genoveva Cuesta, Fernanda Meira, Laura Morata, Pedro Puerta-Alcalde, John Rojas, Berta Torres, Pedro Castro, Jose Muñoz, Josep Mensa, José Antonio Martínez, Gemma Sanjuan, Jordi Vila, Felipe García, Carolina Garcia-Vidal, Alex Soriano, COVID-19-Researcher Group

Erschienen in: Infection | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Assess the impact of viral load estimated by cycle threshold (Ct) of reverse transcription real time-polymerase chain reaction (rRT-PCR) and the days from symptoms onset on mortality in hospitalized patients with COVID19.

Methods

Retrospective observational study of 782 patients with a positive rRT-PCR from a nasopharyngeal swab was performed within the first 24 h from admission. Demographic data, clinical manifestations and laboratory parameters were collected. Uni- and multivariate analyses were performed to identify factors associated with mortality at 60 days.

Results

Ct was divided into three groups and the mortality rate decreased from 27.3 to 20.7% and 9.8% for Ct values of ≤ 20, 21–25 and > 25, respectively (P = 0.0001). The multivariate analysis identified as predictors of mortality, a Ct value < 20 (OR 3.13, CI 95% 1.38–7.10), between 21–25 (OR 2.47, CI 95% 1.32–4.64) with respect to a Ct value > 25. Days from symptoms onset is a variable associated with mortality as well (DSOA) ≤ 6 (OR 1.86, CI 95% 1.00–3.46), among other factors. Patients requiring hospital admission within 6 DSOA with a Ct value ≤ 25 had the highest mortality rate (28%).

Conclusions

The inclusion of Ct values and DSOA in the characterization of study populations could be a useful tool to evaluate the efficacy of antivirals.
Literatur
1.
Zurück zum Zitat Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1240–2.CrossRef Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1240–2.CrossRef
2.
Zurück zum Zitat Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70.CrossRef Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70.CrossRef
3.
Zurück zum Zitat Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323:1–8.CrossRef Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323:1–8.CrossRef
4.
Zurück zum Zitat Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, et al. Personalized therapy approach for hospitalized patients with COVID-19. Clin Infect Dis. 2020;74:127–32.CrossRef Garcia-Vidal C, Moreno-García E, Hernández-Meneses M, et al. Personalized therapy approach for hospitalized patients with COVID-19. Clin Infect Dis. 2020;74:127–32.CrossRef
5.
Zurück zum Zitat Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16–25.CrossRef Zheng Z, Peng F, Xu B, et al. Risk factors of critical and mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16–25.CrossRef
6.
Zurück zum Zitat Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199–206.CrossRef Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020;71(16):2199–206.CrossRef
7.
Zurück zum Zitat Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8: e70.CrossRef Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8: e70.CrossRef
8.
Zurück zum Zitat Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573–86.CrossRef Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020;9:573–86.CrossRef
9.
Zurück zum Zitat Magleby R, Westblade LF, Trzebucki A, et al. Impact of severe acute respiratory sindrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2021;73(11):e4197–205.CrossRef Magleby R, Westblade LF, Trzebucki A, et al. Impact of severe acute respiratory sindrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019. Clin Infect Dis. 2021;73(11):e4197–205.CrossRef
10.
Zurück zum Zitat Huang J-T, Ran R-X, Lv Z-H, et al. Chronological changes of viral shedding in adult inpatients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020;71(16):2158–66.CrossRef Huang J-T, Ran R-X, Lv Z-H, et al. Chronological changes of viral shedding in adult inpatients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020;71(16):2158–66.CrossRef
11.
Zurück zum Zitat Westblade LF, Brar G, Pinheiro LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38:661-671.e2.CrossRef Westblade LF, Brar G, Pinheiro LC, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020;38:661-671.e2.CrossRef
12.
Zurück zum Zitat Faíco-Filho KS, Passarelli VC, Bellei N. Is higher viral load in SARS-CoV-2 associated with death? Am J Trop Med Hyg. 2020;103:2019–21.CrossRef Faíco-Filho KS, Passarelli VC, Bellei N. Is higher viral load in SARS-CoV-2 associated with death? Am J Trop Med Hyg. 2020;103:2019–21.CrossRef
13.
Zurück zum Zitat Prebensen C, Hre PLM, Jonassen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. CID. 2020. Prebensen C, Hre PLM, Jonassen C, et al. SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19. CID. 2020.
14.
Zurück zum Zitat Garcia-Vidal C, Sanjuan G, Puerta-Alcalde P, Moreno-García E, Soriano A. Artificial intelligence to support clinical decision-making processes. EBioMedicine. 2019;46:27–9.CrossRef Garcia-Vidal C, Sanjuan G, Puerta-Alcalde P, Moreno-García E, Soriano A. Artificial intelligence to support clinical decision-making processes. EBioMedicine. 2019;46:27–9.CrossRef
15.
Zurück zum Zitat Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. CID. 2020. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. CID. 2020.
16.
Zurück zum Zitat Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? CID. 2020;1–8. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? CID. 2020;1–8.
17.
Zurück zum Zitat van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. Clin Infect Dis. 2020;1–28 van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. Clin Infect Dis. 2020;1–28
18.
Zurück zum Zitat Xu D, Zhou F, Sun W, et al. Relationship Between serum SARS-CoV-2 nucleic acid (RNAemia) and organ damage in COVID-19 patients: a cohort study. CID. 2020. Xu D, Zhou F, Sun W, et al. Relationship Between serum SARS-CoV-2 nucleic acid (RNAemia) and organ damage in COVID-19 patients: a cohort study. CID. 2020.
19.
Zurück zum Zitat Hagman K, Hedenstierna M, Gille-Johnson P, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. CID. 2021;73(9):e2995–3001.CrossRef Hagman K, Hedenstierna M, Gille-Johnson P, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. CID. 2021;73(9):e2995–3001.CrossRef
20.
Zurück zum Zitat Veyer D, Kernéis S, Poulet G, et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin Infect Dis. 2020;73:e2890–7. Veyer D, Kernéis S, Poulet G, et al. Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value. Clin Infect Dis. 2020;73:e2890–7.
21.
Zurück zum Zitat Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–26.CrossRef Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–26.CrossRef
22.
Zurück zum Zitat Poljak M, Korva M, Gašper NK, et al. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020;58(6):e00599–20.CrossRef Poljak M, Korva M, Gašper NK, et al. Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020;58(6):e00599–20.CrossRef
23.
Zurück zum Zitat Rahman H, Carter I, Basile K, et al. Interpret with caution: an evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus. J Clin Virol. 2020;127: 104374.CrossRef Rahman H, Carter I, Basile K, et al. Interpret with caution: an evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus. J Clin Virol. 2020;127: 104374.CrossRef
24.
Zurück zum Zitat Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–37.CrossRef Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–37.CrossRef
25.
Zurück zum Zitat Kim PS, Read SW, Fauci AS. Therapy for early COVID-19. JAMA. 2020;324(21):2149–50.CrossRef Kim PS, Read SW, Fauci AS. Therapy for early COVID-19. JAMA. 2020;324(21):2149–50.CrossRef
Metadaten
Titel
Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients
verfasst von
Verónica Rico-Caballero
Mariana Fernández
Juan C. Hurtado
M. Angeles Marcos
Celia Cardozo
Laia Albiach
Daiana Agüero
Juan Ambrosioni
Marta Bodro
Mariana Chumbita
Lorena De la Mora
Nicole Garcia-Pouton
Ana Gonzalez-Cordón
Gerard Dueñas
Marta Hernandez-Meneses
Alexy Inciarte
Montse Laguno
Lorna Leal
Irene Macaya
Miguel J. Martínez
Genoveva Cuesta
Fernanda Meira
Laura Morata
Pedro Puerta-Alcalde
John Rojas
Berta Torres
Pedro Castro
Jose Muñoz
Josep Mensa
José Antonio Martínez
Gemma Sanjuan
Jordi Vila
Felipe García
Carolina Garcia-Vidal
Alex Soriano
COVID-19-Researcher Group
Publikationsdatum
13.05.2022
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Infection / Ausgabe 5/2022
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-022-01833-8

Weitere Artikel der Ausgabe 5/2022

Infection 5/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.